Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625883 | 0.94 | PNMT (0.56) | PNMTIDO1TSHRTP53CYP3A4 | |
| SCHEMBL29897365 | 0.87 | PNMT (0.46) | PNMTIDO1TSHRTP53CYP3A4 | |
| SCHEMBL29184213 | 0.87 | TAAR1 (0.54) | PNMTIDO1TSHRTAAR1MAOB | |
| SCHEMBL1363469 | 0.87 | PNMT (0.46) | PNMTIDO1TSHRTP53CYP3A4 | |
| SCHEMBL4349721 | 0.84 | CYP3A4 (0.57) | PNMTIDO1TSHRTP53CYP3A4 | |
| SCHEMBL2451874 | 0.82 | PNMT (0.46) | PNMTIDO1TSHRCYP3A4TAAR1 | |
| SCHEMBL4335695 | 0.82 | PNMT (0.46) | PNMTIDO1CYP3A4TAAR1LOXL2 | |
| SCHEMBL14464883 | 0.82 | PNMT (0.46) | PNMTIDO1TAAR1LOXL2LOX | |
| SCHEMBL20844630 | 0.82 | PNMT (0.46) | PNMTIDO1TSHRTP53CYP3A4 | |
| SCHEMBL1765201 | 0.82 | PNMT (0.46) | PNMTIDO1TAAR1LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126023-B | Pyrazole amide compound as well as preparation method and application thereof | 安徽中医药大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119462392-A | Preparation method of 3, 5-dichloroaniline | 上海交通大学 | 2025-02-18 | — | — | CN | claimed |
| CN-118126023-A | Pyrazole amide compound as well as preparation method and application thereof | 安徽中医药大学 | 2024-06-04 | — | — | CN | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| CN-115028597-B | Method for preparing benzoxazole derivative by TEMPO continuous dehydrocyclization and application | 闽都创新实验室 | 2024-03-26 | — | — | CN | claimed |
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | claimed |
| CN-115286591-B | Synthesis method of drug Tafamidis | 湖南第一师范学院 | 2023-10-20 | — | — | CN | claimed |
| CN-115286591-A | Synthetic method of drug Tafamidis | 湖南第一师范学院 | 2022-11-04 | — | — | CN | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| CN-103108628-A | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LTD | 2013-05-15 | — | — | CN | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | claimed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| US-5853933-A | Photoconductive member and perylene processes | XEROX CORPORATION (US) | 1998-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | PNMT 3102/4885IDO1 481/4885TSHR 1642/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | PNMT 560/4885IDO1 3872/4885TSHR 4856/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | PNMT 1891/4885IDO1 2053/4885TSHR 1654/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | PNMT 137/4885IDO1 2561/4885TSHR 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.